TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04515108

Intervention type: OTHER
Intervention: Clinical assessment
Description: Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.

Intervention type: OTHER
Intervention: Clinical assessment
Description: Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
Study: NCT05172804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting) \[11\].

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
Study: NCT02547051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Allergy Testing and Elimination Diet
Description: Food allergy testing and elimination diet
Study: NCT02336542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
Study: NCT02690714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasminogen (Human) intravenous
Description: Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
Study: NCT01873651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of a Delta III Prosthesis
Description: Implantation of a Delta III Prosthesis
Study: NCT04117698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antitubercular treatment (RIFATER ©)
Description: Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIFINAH ©
Description: RIFINAH ©
Study: NCT00377364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Acetaminophen, Drug: Placebo
Description: Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Acetaminophen, Drug: Placebo
Description: Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
Study: NCT03048877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Oral Tablet
Description: Apatinib Mesylate Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT02145351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive atrial pacing using a dual-chamber pacemaker
Description: The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rate adaptive atrial pacing using a dual-chamber pacemaker
Description: The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker system will be implanted but set to Pacing Off.
Description: The identical pacing system will be implanted, but will be set to Pacing Off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker system will be implanted but set to Pacing Off.
Description: The identical pacing system will be implanted, but will be set to Pacing Off.
Study: NCT02774499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: 0.3mg/kg of methadone given preoperatively (to maximum of 30mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equivalent volume (5mL) of syrup given preoperatively
Study: NCT01970384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: 20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
Study: NCT00758316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracoscopy and Pleurx
Description: Talc poudrage and tunneled pleural catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy
Description: Talc poudrage
Study: NCT02204267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prolonged ECG monitoring
Description: Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG
Study: NCT02497599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111-DOTA-Girentuximab-IRDye800CW
Description: Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: 4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative dual-modality imaging
Description: 7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
Study: NCT04467138

Intervention type: DRUG
Intervention: Omegaven
Description: Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.

Intervention type: DRUG
Intervention: Omegaven
Description: Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
Study: NCT00898313

Intervention type: PROCEDURE
Intervention: fine needle aspiration of the lung
Description: A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.

Intervention type: PROCEDURE
Intervention: thoracentesis
Description: A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
Study: NCT01872104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
Study: NCT00570622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Patients receive 60mg of pioglitazone once a day orally for 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo once a day orally for 9 days
Study: NCT00730665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 100ug, every 12 hours (twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 300ug, every 12 hours (twice a day)
Study: NCT03014349

Intervention type: OTHER
Intervention: Analysis of medical records
Description: Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
Study: NCT00730665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 1mg, every 12 hours (twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 3mg, every 12 hours (twice a day)
Study: NCT03855514

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NuShield
Description: NuShield® is a dehydrated placental allograft.
Study: NCT02053714

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes self-management and education
Study: NCT03662841

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablative chemoembolization (ACE)
Description: Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
Study: NCT04245722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT01867463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvax B
Description: Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra
Description: Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra
Description: Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
Study: NCT03998397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood alcohol concentration withdrawal
Description: The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood alcohol concentration withdrawal
Description: The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
Study: NCT00732485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, sugar pill, from admission to 6 months post burn
Study: NCT03938909

Intervention type: GENETIC
Intervention: cif mtDNA biomarker
Description: The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures

Intervention type: GENETIC
Intervention: cif mtDNA biomarker
Description: The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
Study: NCT04245722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody
Study: NCT03938909

Intervention type: GENETIC
Intervention: cif mtDNA biomarker
Description: The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
Study: NCT04245722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning agent
Study: NCT00098774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 mcg/kg subQ injection daily Day 14 until ANC \> or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
Study: NCT00730665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
Study: NCT04245722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning agent
Study: NCT00730665

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Placebo, every 12 hours (twice a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.